EDIT - CIK 0001650664
Editas Medicine, Inc. (EDIT) reported revenue of $40.52M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $40.52M | +25.4% |
| FY 2024 | $32.31M | -58.6% |
| FY 2023 | $78.12M | +296.3% |
| FY 2022 | $19.71M | -22.8% |
| FY 2021 | $25.54M | -71.8% |
| FY 2020 | $90.73M | +341.9% |
| FY 2019 | $20.53M | -35.7% |
| FY 2018 | $31.94M | +132.6% |
| FY 2017 |
Editas Medicine, Inc. (EDIT) reported revenue of $40.52M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Editas Medicine, Inc.'s revenue grew from $6.05M to $40.52M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $13.73M |
| +126.8% |
| FY 2016 | $6.05M | - |